Baird & Co. Good day, and welcome to the Vertex, Inc. First Quarter 2025 Earnings Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today’s ...

Vertex Pharmaceuticals recently reported a decline in net income and EPS for Q1 2025, despite a rise in revenue, which was accompanied by a large $379 million impairment charge related to its ...

Vertex Pharmaceuticals is expanding its manufacturing capabilities for its gene therapy Casgevy, signaling growing demand for the treatment. Business of Pride Join the Boston Business Journal for ...

Vertex has recorded some 25,000 prescriptions for Journavx since its January approval and is in the process of getting big PBMs to cover the non-opioid pain drug. In what analysts called a “sticker ...

May 5 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF ...

You can reach Jason on Signal at JasonMast.05. Vertex Pharmaceuticals on Monday reported disappointing first-quarter earnings impacted by weaker-than-expected sales of its drugs for cystic ...

Google updated the documentation for the Google-Extended user agent, which publishers can use to control whether Google Gemini and Vertex use their data for training purposes or for grounding AI ...

The scenarios can be repeated as often as it takes for good habit patterns to form. Vertex Solutions’ ITDs are utilized for the U.S. Air Force and Navy’s undergraduate pilot training ...

At the 2025 Napa Valley Biotech Forum, JPMorgan analyst Jessica Fye walked away with a bullish tone after conversations with Vertex CEO Reshma Kewalramani and Senior Vice President of Investor ...

Vertex will not advance VX-264 trials after the study failed to meet efficacy endpoints, despite being generally safe and well tolerated. Zimislecel, Vertex’s islet cell therapy, remains on ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

Vertex Pharmaceuticals (Nasdaq: VRTX) specialises in treatments for rare diseases. It has eight approved medicines on the market. Seven of these are medicines for various types of cystic fibrosis ...